| Course | HIM 615 Health Care Information Systems and Technology |
|---|---|
| Topic | Topic 8 |
| Paper type | Runner-up selection defense |
| Length | About 970 words, 3 pages |
| Format | APA 7 student paper |
| School | Grand Canyon University (GCU) |
| Program | MS in Health Informatics |
| Updated | September 2026 |
Free sample paper for HIM 615 Topic 8
Finalist B, With Finalist A's Case Stated in Full: A Selection Recommendation to the Paloma Basin Board That Argues Against Itself
[Author Name]
College of Nursing and Health Care Professions, Grand Canyon University
HIM-615: Health Care Information Systems and Technology
Topic 8 Assignment
[Instructor Name]
[Date]
The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.
Finalist B, With Finalist A's Case Stated in Full: A Selection Recommendation to the Paloma Basin Board That Argues Against Itself
Decision Requested
The selection committee recommends that the Paloma Basin Health board approve Finalist B as the system's enterprise electronic health record, at an illustrative ten-year cost of $105.0 million, and authorize the chief executive to sign the negotiated agreement after counsel's final review. Finalist A is the runner-up. On the committee's weighted scoring, B scored 3.92 of 5 and A scored 3.50. The margin is clear but not overwhelming, and this recommendation therefore spends as much space on A as on B.
The Case for Finalist A
A's strongest advocate on the committee, the medical director of oncology, would put the case this way. In the unscripted sessions, oncology physicians and nurses preferred A's chemotherapy ordering and treatment planning workflows by a wide margin; they completed a regimen order in fewer steps and found dose adjustments clearer. Oncology is where ordering errors are most dangerous. A's license costs $12.0 million less over ten years. A already runs a results interface with our reference laboratory and already segments substance use treatment records in production at two behavioral health customers, a capability B has only promised. And A's clinical workflow score, the most heavily weighted criterion, was the higher of the two.
Every one of those points is accurate. The committee accepted them in its scoring, and the response below does not dispute them.
Why Finalist B Still Prevails
Table 1
Weighted Scores Agreed Before Demonstrations
| Criterion | Weight | Finalist A | Finalist B |
|---|---|---|---|
| Clinical workflow and usability | 30% | 4.0 | 3.8 |
| Ten-year total cost | 20% | 3.2 | 4.0 |
| Interoperability proven in production | 20% | 3.4 | 3.9 |
| Contract terms after negotiation | 15% | 3.0 | 3.8 |
| Implementation and single record | 15% | 3.5 | 4.2 |
| Weighted score | 3.50 | 3.92 |
Weighing Each of A's Advantages
The response uses only evidence the committee gathered before this recommendation was written. A's lower license does not survive a full cost count: once hosting, the interfaces beyond its included 20 and the internal analysts a self-hosted system requires are added, A costs $9.7 million more over ten years. On interoperability, B has seven of the network's exchanges proven in production in this state against A's five, including immunization registry query and prescription monitoring. A's live laboratory interface is real, and B's new build is included in its contract at no charge. On contract terms, B accepted all six changes the committee rated essential, including removal of the clause restricting staff from discussing safety problems; A accepted four and would not make its indemnification mutual. B also runs inpatient and clinic care on one database, while A links separate inpatient and ambulatory databases through an internal interface, which matters for a system in which patients move between sites every day.
A's oncology advantage is the one the committee could not answer with evidence from elsewhere, and it is carried below as the first residual risk rather than argued away. Vendors do not design with users to the same standard (Ratwani et al., 2015), and a specialty such as oncology, with complex regimens and narrow dosing margins, is where the gap between two products is most likely to reach a patient. The committee therefore did not average the oncology preference into the general workflow score and move on; it treated the preference as a finding that needs its own mitigation, its own owner and its own measure after go-live.
Sensitivity
The committee tested how far the weights and scores would have to move before A wins. At the agreed weights, no possible clinical workflow score for A reverses the result, since A would need more than the maximum of 5. The weight on clinical workflow would have to rise from 30% to about 78% before A's advantage there outweighed B's elsewhere. If A conceded every interface and matched B's staffing, closing the cost gap, B would still lead, 3.92 to 3.66. If B failed to deliver record segmentation and its interoperability score fell to 3.0, B would still lead, 3.74 to 3.50. With both changes together, B leads narrowly, 3.74 to 3.66. The committee judges that the result would survive any single plausible change and most combinations.
Residual Risks of the Chosen System
Table 2
Residual Risks, Mitigations and Commitments
| Risk | Mitigation | Owner | Contractual commitment |
|---|---|---|---|
| Oncology workflows weaker than A's | Oncology build led by oncology clinicians, with usability testing before go-live | Medical director of oncology | 1,200 hours of vendor oncology specialists included |
| Substance use record segmentation not yet in production | Behavioral health clinics join only after segmentation is proven | Behavioral health director and privacy officer | Delivery date with vendor paying interim interface costs if missed |
| Subscription increases after year five | Budgeted at the cap | Chief financial officer | Cap of 3% a year for the full term |
| New laboratory interface | Built and tested before cutover | Integration manager | Included at no charge |
Dissent, Recorded
The oncology group did not change its view, and its members voted for A. Their concern is recorded in the committee minutes, and the medical director of oncology has been appointed to the build governance council with authority over oncology order sets. Koppel and Lehmann (2015) observed that hospitals increasingly commit to a single enterprise vendor for many years, which makes it more important, not less, that concerns raised at selection are carried into the build. Cresswell et al. (2013) similarly emphasized engaging clinicians throughout implementation rather than only at the start. A dissent heard now is cheaper to address than the same dissent discovered on the first night of go-live.
The Decision
The committee asks the board to approve Finalist B on the negotiated terms, to fund the oncology build and usability testing in the implementation budget, and to receive a report at twelve months on the oncology workflows, measured by ordering time and pharmacist interventions on chemotherapy orders, compared with the specialists' baseline.
References
Cresswell, K. M., Bates, D. W., & Sheikh, A. (2013). Ten key considerations for the successful implementation and adoption of large-scale health information technology. Journal of the American Medical Informatics Association, 20(e1), e9-e13. https://doi.org/10.1136/amiajnl-2013-001684
Koppel, R., & Lehmann, C. U. (2015). Implications of an emerging EHR monoculture for hospitals and healthcare systems. Journal of the American Medical Informatics Association, 22(2), 465-471. https://doi.org/10.1136/amiajnl-2014-003023
Ratwani, R. M., Fairbanks, R. J., Hettinger, A. Z., & Benda, N. C. (2015). Electronic health record usability: Analysis of the user-centered design processes of eleven electronic health record vendors. Journal of the American Medical Informatics Association, 22(6), 1179-1182. https://doi.org/10.1093/jamia/ocv050
Reading the GCU HIM 615 Topic 8 instructions
The Topic 8 instructions in HIM-615 ask students to present a final system selection recommendation. Weak submissions present the winner alone. The assignment rewards recommendations that state the decision first, set out the runner-up's case as its strongest supporter would, and answer each advantage with evidence already gathered during selection. Students should test how far weights or scores would need to move to change the result, list residual risks of the chosen system with mitigations, owners and contract commitments, record dissent and close with a specific request to the decision makers.
Inside the HIM 615 Topic 8 example
The finished recommendation asks a composite hospital's board to approve one finalist and spends as much effort on the runner-up as on the winner. The runner-up's advantages are conceded in full: specialty clinicians preferred its oncology workflows during the unscripted session, and its license costs less. The recommendation then shows why the winner still prevails, drawing on evidence already gathered: a lower ten-year cost once interfaces and internal staff are counted, more exchanges proven in production, contract terms with clearer remedies and a single record across inpatient and clinic care. A sensitivity passage shows how far the weights would have to move before the runner-up wins. Residual risks of the chosen system are listed with mitigations, beginning with the oncology gap the specialists identified.
HIM 615 Topic 8 rubric: what Excellent looks like
Faculty grading the selection defense reward a tested decision. Excellent recommendations concede the runner-up's real strengths, including clinician preference, and answer them with cost, interoperability and contract evidence gathered earlier. Credit goes to sensitivity analysis that names the combination of changes that nearly reverses the result. The rubric values residual risks tied to contractual commitments secured in negotiation. The highest level records dissent and gives the dissenting group authority in the build. Recommendations that reduce the runner-up to a line in a table, or that justify the choice with new arguments, usually land in a middle band.
HIM 615 Topic 8 help before you submit
Recommendations that present the winner alone, with the runner-up reduced to a line in a table, lose marks at once, because the board cannot tell whether the decision was tested. Weakening the runner-up's case to make the choice look obvious is noticed quickly, especially when clinicians on the committee preferred it. Papers that justify the choice with new arguments, rather than the cost, exchange and contract evidence already assembled, look as if the decision came first and the reasons afterward. Drafts with no sensitivity analysis cannot say whether the result would survive a modest change in weighting. Some papers treat the recommendation as the end of risk and list none for the chosen system. Dissent left unrecorded tends to return during implementation, when it is far more expensive to address.
Get an HIM-615 Topic 8 example written to your instructions
Send the HIM-615 Topic 8 instructions and the rubric posted in your classroom, together with the finalists, scores or evidence your assignment provides. We write a custom example to those criteria, with the answer stated first, the runner-up argued at full strength, each advantage answered on evidence, a sensitivity test and residual risks owned, in 24 to 48 hours. The first one is free.
More HIM 615 papers and MS in Health Informatics samples
- HIM 615 Topic 1: Baseline Needs Assessment
- HIM 615 Topic 2: Vendor Demonstration Script
- HIM 615 Topic 3: Total Cost of Ownership Model
- HIM 615 Topic 4: Interoperability Claim Test
- HIM 615 Topic 5: Vendor Contract Obligations Review
- HIM 615 Topic 6: Go-live Strategy Decision Paper
- HIM 615 Topic 7: Post-implementation Adoption Review
- HIM 650 Topic 8: Vendor-independent Lifecycle Strategy
- HIM 515 Topic 8: Informatics Accountability Position
HIM 615 Topic 8 questions, answered
Why give so much space to the system that lost?
Because the board is being asked to trust a decision it did not watch being made. Setting out the runner-up at its strongest, then answering each advantage on evidence, shows the choice survived a real test. It also protects the organization later: when the chosen system disappoints somewhere, the record shows that trade-off was known, weighed and accepted rather than overlooked.
What if clinicians preferred the runner-up?
Say so plainly and weigh it seriously, since clinician experience predicts much of how a system is received. The recommendation can still choose the other finalist if cost, interoperability or contract evidence outweighs that preference, but it must show the weighing and carry the clinicians' concern into implementation as a named risk with an owner. Hiding the preference invites it to resurface as resistance.
Does this repeat the requirements work from Topic 1?
No. Requirements set the criteria before any product was seen, and each later topic gathered evidence against them. This recommendation is the point where that evidence is combined into one decision and defended. It should draw on the earlier cost, demonstration, exchange and contract findings rather than introduce new reasons, since reasons appearing only at the end suggest the decision preceded the analysis.
Where can I find a free HIM 615 Topic 8 sample paper?
The full recommendation is above, with the decision, the case for Finalist A, the scores, each advantage weighed, sensitivity, residual risks, recorded dissent and the decision asked of the board. Share your finalists for a free worked defense.
Why does Finalist B win in HIM 615 Topic 8?
It costs less over ten years, proves more exchanges in production, accepted every essential contract change and runs one record across hospitals and clinics, while A's oncology edge is carried as a risk.